ABSTRACT
<p><b>OBJECTIVE</b>To detect the expression of microRNA-210(miR-210) in childhood acute lymphoblastic leukemia(ALL), and to evaluate the role of the joint detection of miR-210 and MRD in the prognosis and clinical treatment of pediatric ALL.</p><p><b>METHODS</b>Eighty-eight children diagnosed with ALL were included in the study. miR-210 was quantitatively detected by real-time quantitative polymerase chain reaction(RQ-PCR) in 88 ALL patients. The average Ct value of samples obtained from 5 pediatric ALL patients with long-term complete continuous remission (CCR>5 years) was used as a calibrator. The expression levels of miR-210 in newly diagnosed patients was calculated by the 2method and presented as multiple changes compared with that of the 5 CCR patients.</p><p><b>RESULTS</b>The expression of miR-210 in the favorable prognosis group was significantly higher than that in the unfavorable prognosis group (10.64±1.5 vs 3.27±0.68)(P<0.05). Compared with the miR-210 high-expression group, poorer relapse-free survival(RFS), event-free survival(EFS) and overall survival(OS) (P all <0.001) were found in the low-expression group. Based on the expression of miR-210 and MRD, the 88 cases were divided into 3 groups. The relapse rate of miR-210-MRD high-risk group (70%) was significantly higher than that of the miR-210-MRD middle-risk group(6.25%) and miR-210-MRD low-risk group (2.1%). Kaplan-Meier survival analysis demonstrated that the miR-210-MRD high-risk group had poorer RFS, EFS and OS than those in other 2 groups (P all <0.01).</p><p><b>CONCLUSION</b>The expression level of miR-210 is an independent prognostic factor for pediatric ALL, and the miR-210 is a good useful indicator for predicting the relapse and induction failure of childhood ALL. Joint detection of miR-210 and MRD can help predict outcomes more precisely, thus may be used as an effective mean of determining prognosis, monitoring recurrence, and guiding treatment.</p>
ABSTRACT
Objective To analyze the clinical data of 12 children with advanced Wlims' tumor in children from Feb.2009 to Jun.2012.All cases were diagnosed by pathology and to analysis the clinic efficacy and treatment experience were analyzed.Methods Of 12 patients,10 cases were male and 2 cases were female.The medium age of 12 patients was 2.54 years old(9 months-15 years old).According to pathological stage and clinical stage of The National Wilms' Tumor Study Group(NWTSG),5 cases belonged to stage lⅢ,and 7 cases stage Ⅳ.Six cases were well-differentiated tissue type,and 6 cases were poorly differentiated tissue type according to NWTSG.In all patients,different ways of chemotherapy and radiotherapy were selected according to clinical stage and tissue type differentiation.If a patient had repeated recurrence after common surgery and chemotherapy,would treated by antologous peripheral blood stem cell transplantation(APBSCT).Statistic analysis was used to analyze the clinical characters and efficacy and prognosis for 12 patients.Results 1.Initial symptoms:in 12 cases,8 cases presented abdominal mass (66.6％),2 cases with abdominal pain and fever(12.7％),and 2 cases with hematuria(12.7％).2.Eleven cases followed up to Jan.2013,the medium time was 31.5 months(8-131 months).Of 12 cases,1 case give up therapy and follow-up and 11 cases were followed up.Of those 11 cases followed-up,4 cases had complete remission(CR),and 1 case had remission in part(PR),the conditions of 5 cases were progressively worse,1 case replapsed,and 4 patients died.Total survival rate was 63.63％ (7/11 cases),and mortality was 36.37％ (4/11 cases),and free survival rate was 36.37％ (4/11 cases),of that,1 patient of stage Ⅳ,relapsed 3 times after common radiotherapy and chemotherapy,achieved complete remission after high dose chemotherapy (Melphalan + Carboplatin + Etoposide,CEM) and APBSCT.The estimated 3-yearsurvival rate was 51.4％.Conclusions The prognosis of advanced Wilms' tumor is poor,and the mortality is still high.High dose chemotherapy with APBSCT may be a valuable method for advanced cases.
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the efficacy of high dose chemotherapy combined with autologous peripheral blood stem cell transplantation (APBSCT) for the treatment of neural ectodermal solid tumor originated from neural crest in children.</p><p><b>METHODS</b>Twenty-three children at a medium age of 5.8 + or - 3.5 years with neural ectodermal solid tumor originated from neural crest were enrolled. Of the 23 children, 20 with stage IV neuroblastoma (9 were in complete remission, 7 were in partial remission and 4 were in progressive disease), 2 with stage IV primitive neuroectodermal tumor (PNET) in complete remission, and 1 with retinoblastoma in partial remission. Before APBSCT the children received 8.0 + or - 4.3 courses of chemotherapy. During chemotherapy the autologous peripheral blood stem cells were harvested and the tumor excision was performed. Then APBSCT was performed.</p><p><b>RESULTS</b>The reconstruction of the hematopoietic system was noted in 19 of 20 children with stage IV neuroblastoma 16.5 + or - 0.9 days after transplantation. A follow-up (median 15.8 months) was done in these children. The follow-up showed that the survival rate in children in complete remission before transplantation was 100%, 57% in those in partial remission, and none of children in progressive disease survived (P<0.05). The total survival rate was 67% in children with neuroblastoma. The child with retinoblastoma had complete remission in a 6-months follow-up. The tumors recurred in children with PNET 5 to 8 months after transplantation and all died within one year after transplantation.</p><p><b>CONCLUSIONS</b>High dose chemotherapy combined with APBSCT can result in a good outcome in children with neural ectodermal solid tumor originated from neural crest in complete remission before transplantation and can improve the outcome in patients in partial remission before transplantation. However, the children with PNET, even in complete remission before transplantation, do not respond to the therapy.</p>